Maternal Organokines and Neonatal Growth
Author Information
Author(s): Valencia-Ortega Jorge, Galicia-Hernández Victoria, Castillo-Santos Andrea, Molerés-Orduña Miranda, Arceo-Cerna Carla, Perichart-Perera Otilia, Rodríguez-Cano Ameyalli M., Rodríguez-Hernández Carolina, Estrada-Gutierrez Guadalupe, Camacho-Arroyo Ignacio, Solis-Paredes Juan Mario
Primary Institution: Instituto Nacional de Perinatología
Hypothesis
During pregnancy, PGRN, AFABP, BDNF, and FGF21 regulate maternal glucose and lipid metabolism, which may influence neonatal anthropometric outcomes.
Conclusion
Maternal PGRN, AFABP, and BDNF concentrations vary throughout pregnancy and can predict neonatal weight, length, and fat mass percentage.
Supporting Evidence
- Maternal PGRN concentrations increase as pregnancy progresses.
- Third-trimester PGRN concentrations predict neonatal weight and length.
- Maternal age and BDNF concentrations also predict neonatal length.
- Maternal obesity affects AFABP and FGF21 concentrations.
- Neonatal fat mass percentage is predicted by maternal pBMI and GWG.
Takeaway
This study found that certain proteins in pregnant mothers can help predict how big and healthy their babies will be when they are born.
Methodology
Longitudinal study measuring maternal organokine concentrations and neonatal anthropometric characteristics.
Potential Biases
Potential bias due to self-reported pregestational weight and small sample sizes in some categories.
Limitations
The study design does not establish causal relationships and had a small sample size for some groups.
Participant Demographics
Healthy adult pregnant women (≥18 years old) with a pregestational BMI ≥18.5 kg/m2.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website